Journal
ANTIBODIES
Volume 12, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/antib12030046
Keywords
monoclonal antibodies; immunotherapy; synthetic nucleic acids; therapeutic delivery; accessibility; utility; diseases; in vivo production; administration logistics; cost reduction; biopharmaceuticals
Categories
Ask authors/readers for more resources
Harnessing the immune system to combat disease has transformed medical treatment. Monoclonal antibodies have emerged as important immunotherapeutic agents with clinical relevance in treating a wide range of diseases. However, their production and administration are costly, time-consuming, and have limitations. Researchers are exploring new methods to increase the accessibility and utility of monoclonal antibody treatments.
Harnessing the immune system to combat disease has revolutionized medical treatment. Monoclonal antibodies (mAbs), in particular, have emerged as important immunotherapeutic agents with clinical relevance in treating a wide range of diseases, including allergies, autoimmune diseases, neurodegenerative disorders, cancer, and infectious diseases. These mAbs are developed from naturally occurring antibodies and target specific epitopes of single molecules, minimizing off-target effects. Antibodies can also be designed to target particular pathogens or modulate immune function by activating or suppressing certain pathways. Despite their benefit for patients, the production and administration of monoclonal antibody therapeutics are laborious, costly, and time-consuming. Administration often requires inpatient stays and repeated dosing to maintain therapeutic levels, limiting their use in underserved populations and developing countries. Researchers are developing alternate methods to deliver monoclonal antibodies, including synthetic nucleic acid-based delivery, to overcome these limitations. These methods allow for in vivo production of monoclonal antibodies, which would significantly reduce costs and simplify administration logistics. This review explores new methods for monoclonal antibody delivery, including synthetic nucleic acids, and their potential to increase the accessibility and utility of life-saving treatments for several diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available